<DOC>
	<DOCNO>NCT02915705</DOCNO>
	<brief_summary>UX023-CL301 multicenter , randomize , open-label , Phase 3 study compare efficacy safety KRN23 active control ( oral phosphate/active vitamin D therapy ) child XLH ( age 1 ≤12 year ) radiographic evidence rickets , open epiphysis , receive oral phosphate/active vitamin D therapy ≥ 6-12 consecutive month prior screen . Approximately 60 subject randomize 1:1 receive open-label KRN23 administer subcutaneous injection oral phosphate active vitamin D therapy total 64 week .</brief_summary>
	<brief_title>Efficacy Safety KRN23 Versus Oral Phosphate Active Vitamin D Treatment Pediatric Patients With X Linked Hypophosphatemia ( XLH )</brief_title>
	<detailed_description />
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Male female , age 1 ≤12 year radiographic evidence rickets determine central read 2 . PHEX mutation variant uncertain significance either patient directly relate family member appropriate Xlinked inheritance 3 . Biochemical finding associate XLH : Serum phosphorus &lt; 3.0 mg/dL ( 0.97 mmol/L ) 4 . Serum creatinine within ageadjusted normal range 5 . Serum 25 ( OH ) D low limit normal ( ≥16 ng/mL ) Screening Visit 6 . Have receive oral phosphate active vitamin D therapy ≥ 12 consecutive month ( child ≥3 year age ) ≥ 6 consecutive month ( child &lt; 3 year age ) prior Screening Visit 7 . Willing provide access prior medical record collection historical growth radiographic data disease history . 8 . Provide write verbal assent ( appropriate subject region ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure . 9 . Must , opinion investigator , willing able complete aspect study , adhere study visit schedule comply assessment . 10 . Females reach menarche must negative pregnancy test Screening undergo additional pregnancy test study . If sexually active , male female subject must willing use highly effective method ( ) contraception duration study . 1 . Tanner stage 4 high physical examination 2 . Height percentile &gt; 50 % base countryspecific norm 3 . Use aluminum hydroxide antacid ( e.g . Maalox® Mylanta® ) , systemic corticosteroid , acetazolamide , thiazide within 7 day prior Screening Visit 4 . Current prior use leuprorelin ( e.g. , Lupron® , Viadur® , Eligard® ) , triptorelin ( TRELSTAR® ) , goserelin ( Zoladex® ) , drug know delay puberty 5 . Use growth hormone therapy within 12 month Screening Visit 6 . Presence nephrocalcinosis renal ultrasound grade 4 7 . Planned recommend orthopedic surgery , include staple , 8plates osteotomy , within clinical trial period 8 . Hypocalcemia hypercalcemia , define serum calcium level outside ageadjusted normal limit 9 . Evidence hyperparathyroidism ( PTH level 2.5X upper limit normal [ ULN ] ) 10 . Use medication suppress PTH ( e.g. , cinacalcet , calcimimetics ) within 2 month prior Screening Visit 11 . Presence history condition , view investigator , place subject high risk poor treatment compliance complete study . 12 . Presence concurrent disease condition would interfere study participation affect safety 13 . History recurrent infection predisposition infection , know immunodeficiency 14 . Use therapeutic monoclonal antibody within 90 day prior Screening Visit history allergic anaphylactic reaction monoclonal antibody 15 . Presence history hypersensitivity KRN23 excipients , judgment investigator , place subject increase risk adverse effect . 16 . Use investigational product investigational medical device within 30 day prior screen , requirement investigational agent prior completion schedule study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>